Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial

This publication has 16 references indexed in Scilit:

• Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma
  British Journal of Cancer, 2016
• Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
  Journal of Clinical Oncology, 2014
• Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
  Journal of Clinical Oncology, 2014
• Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
  New England Journal of Medicine, 2013
• External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
  The Lancet Oncology, 2013
• Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin
  Journal of Clinical Oncology, 2012
• Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
  The Lancet Oncology, 2012
• Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
  Journal of Clinical Oncology, 2010
• Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
  New England Journal of Medicine, 2007
• Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
  New England Journal of Medicine, 2007